Log in

NYSE:BLUBellus Health Stock Price, Forecast & News

$2.53
-0.05 (-1.94 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.30
Now: $2.53
$2.61
50-Day Range
$2.93
MA: $9.31
$12.02
52-Week Range
$2.30
Now: $2.53
$12.03
Volume5.51 million shs
Average Volume1.75 million shs
Market Capitalization$152.79 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone450-680-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees10
Market Cap$152.79 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.

Bellus Health (NYSE:BLU) Frequently Asked Questions

How has Bellus Health's stock been impacted by COVID-19 (Coronavirus)?

Bellus Health's stock was trading at $9.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLU stock has decreased by 73.1% and is now trading at $2.53. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bellus Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellus Health in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellus Health.

When is Bellus Health's next earnings date?

Bellus Health is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Bellus Health.

How were Bellus Health's earnings last quarter?

Bellus Health Inc. (NYSE:BLU) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. View Bellus Health's earnings history.

What price target have analysts set for BLU?

8 brokers have issued twelve-month price objectives for Bellus Health's stock. Their forecasts range from $6.00 to $28.00. On average, they expect Bellus Health's stock price to reach $14.94 in the next year. This suggests a possible upside of 490.5% from the stock's current price. View analysts' price targets for Bellus Health.

Has Bellus Health been receiving favorable news coverage?

Media headlines about BLU stock have trended somewhat negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellus Health earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Bellus Health.

Who are some of Bellus Health's key competitors?

What other stocks do shareholders of Bellus Health own?

Who are Bellus Health's key executives?

Bellus Health's management team includes the following people:
  • Mr. Roberto Bellini, Pres, CEO & Director (Age 39)
  • Mr. François Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 56)
  • Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 62)
  • Mr. Tony Matzouranis, VP of Bus. Devel. (Age 46)
  • Dr. Catherine Bonuccelli, Chief Medical Officer

What is Bellus Health's stock symbol?

Bellus Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "BLU."

How do I buy shares of Bellus Health?

Shares of BLU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bellus Health's stock price today?

One share of BLU stock can currently be purchased for approximately $2.53.

How big of a company is Bellus Health?

Bellus Health has a market capitalization of $152.79 million. Bellus Health employs 10 workers across the globe.

What is Bellus Health's official website?

The official website for Bellus Health is www.bellushealth.com.

How can I contact Bellus Health?

The company can be reached via phone at 450-680-4500.

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.